NASDAQ · AVR
Anteris Technologies Global Corp.
$6.42+$0.32 (+5.25%)
Anteris Technologies Global Corp.’s quoted price sits in the lower half of its reported 52-week range, 41.95% below the high.
Loading market information…
NASDAQ · PROF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Profound Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Profound Medical Corp.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.19. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Profound Medical Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.36-24.14% vs estimate | $2.62M-44.12% vs estimate |
|---|
| Q4 2024 | Mar 6, 2025 | -$0.20+35.48% vs estimate | $5.33M-9.99% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.38-26.67% vs estimate | $3.83M-35.36% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $11.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.42+$0.32 (+5.25%)
Anteris Technologies Global Corp.’s quoted price sits in the lower half of its reported 52-week range, 41.95% below the high.
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
$3.86-$0.07 (-1.78%)
TriSalus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
$2.38+$0.12 (+5.31%)
Neuronetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.81% below the high.
$1.73+$0.02 (+1.17%)
MaxCyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.42% below the high.
$1.17-$0.08 (-6.02%)
Perspective Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.01% below the high.
$4.19+$0.02 (+0.48%)
Owlet, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.27% below the high.
$3.25-$0.04 (-1.22%)
Armata Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.3% below the high.
